

# Medlab Clinical Ltd

00:09 18 Jun 2019

## Medlab Clinical receives human ethics approval for cannabis-based pain management medicine trial

Medlab Clinical Ltd (ASX:MDC) has received human ethics approval for the second trial of its cannabis-based medicine NanaBis™.

Known as an Observational Study, the data from this study will be used to enhance regulatory package for potential drug approval.

The trial will follow how Australian doctors use NanaBis, provide patient feedback and as a result will provide valuable data aimed to support its global regulatory efforts.

The cost of the trial will be partly funded by successful participants as they will have access to NanaBis at a significantly reduced price.

READ: Medlab Clinical signs second international distribution deal for NanaBis

Medlab CEO Dr Sean Hall said: "This trial is very important to us as it allows MDC to leverage the Australian Special Access Scheme (SAS), follow the patients closely, but more-so publish and use the forthcoming data to bolster all our regulatory efforts as it relates to NanaBis.

"In talks with a number of regulatory bodies, we were offered a unique ability to use this type of data in an effort to diminish the otherwise prescribed number of people needed to finalise drug application work.

"This trial is happening in parallel to the almost completed Royal North Shore (RNS) trial.

"With regards to the work at RNS, early data received is very pleasing and this coupled with the learnings from the current Australian SAS usage, NanaBis is a strong contender for pain management and in my mind a viable pain management medication."

Medlab expects to roll this trial out to 2,000 patients across Australia as quick as possible, making it one of the most significant cannabis trials to date.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is

**Price:** 0.385

**Market Cap:** \$82.92 m

### 1 Year Share Price Graph



### Share Information

**Code:** MDC

**Listing:** ASX

**52 week High Low**  
0.56 0.335

**Sector:** Cannabis

**Website:** www.medlab.co

### Company Synopsis:

Medlab Clinical Ltd (ASX:MDC) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).